Absolutely no mention of AstraZeneca, at all. Another disappearing partner perhaps (this time significant). What happened to the Development and Option Agreement with AZ? Shareholders deserve much better. Hello ASIC!!
I’ve been adamant for years that DEP-Docetaxel is a commercial dud and going nowhere. My position is now only strengthened by the fact that DEP-Docetaxel was not accepted for presentation at ASCO in June.
Absolutely no mention of AstraZeneca, at all. Another...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
-0.001(1.00%) |
Mkt cap ! $40.79M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $24.18K | 241.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2499 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 428888 | 7 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.3¢ | 10.5¢ | 10.0¢ | 168392 | ||
| Last updated 15.48pm 13/06/2024 ? | |||||
| SPL (ASX) Chart |